MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on ...
Bragar Eagel & Squire, P.C. is investigating Medpace Holdings, Inc. following a significant drop in its stock price and discrepancies in reported book-to-bill ratios. Concerns arose after Medpace disclosed a lower-than-expected book-to-bill ratio of 1.04, with the CEO attributing it to cancellations, contradicting earlier positive statements. The firm is inviting investors who suffered losses to contact them to discuss potential legal claims against Medpace.
Bragar Eagel & Squire Investigates Potential Claims Against Medpace
Bragar Eagel & Squire, P.C. has launched an investigation into Medpace Holdings, Inc. (MEDP) regarding potential violations of federal securities laws following a 15.9% stock price drop. While the company's Q4 2025 earnings exceeded expectations, concerns arose regarding a book-to-bill ratio miss and the highest level of project cancellations in over a year.
MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace Holdings, Inc. following a significant drop in its stock price. This investigation comes after Medpace reported Q4 2025 earnings with a lower-than-expected book-to-bill ratio and higher cancellations, contradicting previous optimistic statements from the CEO. Stockholders who suffered losses are encouraged to contact the firm to discuss their legal rights regarding potential violations of federal securities laws.
Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) for potential securities law claims. The investigation focuses on whether the company's statements about its clinical-trial booking pipeline were inconsistent with internal data showing elevated cancellation rates and a deteriorating book-to-bill ratio. This follows a Q4 2025 earnings report where the book-to-bill ratio fell to 1.04, significantly below historical trends and CEO projections, leading to a 15.9% drop in Medpace shares.
Medpace stock rating upgraded to Hold by TD Cowen on valuation
TD Cowen upgraded Medpace Holdings Inc. (NASDAQ:MEDP) to Hold from Sell, adjusting its price target to $419 from $462, aligning with the stock's current trading price after a year-to-date decline. The analyst cited a valuation re-rating and the company's focus on biotech within an improving macro environment. Despite a strong Q4 2025 earnings report, analysts have mixed outlooks, with some upgrading ratings due to biotech funding and AI potential, while others lowered price targets due to elevated cancellations.
Jefferies upgrades Medpace Holdings (MEDP)
Jefferies has upgraded Medpace Holdings (MEDP). This brief article indicates a positive re-evaluation of the company by the financial firm. Further details on the reasons for the upgrade are not provided in this snippet.
Rep. Gilbert Ray Cisneros, Jr. Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Shares
Representative Gilbert Ray Cisneros, Jr. recently sold between $15,001 and $50,000 worth of Medpace Holdings, Inc. (NASDAQ:MEDP) stock on January 15th, while also making several smaller purchases in other companies. Medpace exceeded its quarterly earnings expectations with $4.67 EPS and $708.45M in revenue, and set strong FY2026 guidance, yet the stock maintains a "Hold" rating from analysts with an average price target of $487.36. Insider selling has been notable recently, with executives selling substantial amounts, though institutional investors hold a significant majority stake.
Pallas Capital Advisors LLC Increases Position in Medpace Holdings, Inc. $MEDP
Pallas Capital Advisors LLC significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 154.1% in the third quarter, now holding 4,573 shares valued at approximately $2.35 million. This increase comes despite substantial insider selling activity, with the CFO and VP offloading shares totaling over $13 million. Medpace reported strong quarterly results, beating EPS and revenue estimates, and provided positive FY2026 guidance, though analysts maintain a "Hold" rating with an average target price of $487.36.
The 5 Most Interesting Analyst Questions From Medpace's Q4 Earnings Call
Medpace's Q4 earnings call revealed robust revenue growth but also highlighted concerns over rising cancellation rates, especially in metabolic trials, and margin pressure. Despite these challenges, management described the business environment as "adequate." Analysts focused on direct fee revenue, cancellation drivers, concentration risks in metabolic trials, and the impact of AI on productivity.
Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of "Hold" by Analysts
Analysts have issued a "Hold" rating for Medpace Holdings, Inc. (NASDAQ:MEDP), with an average 1-year price target of $487.36. The company recently surpassed quarterly earnings and revenue estimates and provided positive FY2026 guidance. Despite significant insider selling, institutional investors have been adjusting their holdings, and insiders still retain a substantial ownership percentage.
Cibc World Market Inc. Makes New $5.03 Million Investment in Medpace Holdings, Inc. $MEDP
Cibc World Market Inc. has invested $5.03 million in Medpace Holdings, Inc. by acquiring 9,788 shares in the third quarter. This investment comes as Medpace reported strong quarterly earnings, surpassing analyst expectations with $4.67 EPS and $708.45 million in revenue, leading to a "Hold" average rating from analysts despite some insider selling. Institutional investors own a significant 77.98% of the company's stock.
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported Earnings, And Analysts Cut Their Target Price
Medpace Holdings reported annual results, with revenues of US$2.5 billion matching analyst forecasts and EPS of US$15.28 beating expectations. Despite an improved earnings per share outlook for 2026, analysts cut their average price target by 10% to US$491, signaling other concerns. The company's revenue growth is projected to slow to 11% annually, but still outperform the industry average of 6.2%.
Prescott Group Capital Management L.L.C. Cuts Position in Medpace Holdings, Inc. $MEDP
Prescott Group Capital Management L.L.C. significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 40.0% in the third quarter, holding 6,000 shares worth $3.085 million. This reduction comes despite several other large institutions increasing their positions, and Medpace reporting strong quarterly earnings with a 32% year-over-year revenue increase and positive FY2026 EPS guidance. Institutional ownership remains high at nearly 78%, though analysts hold a mixed "Hold" consensus rating.
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Medpace Holdings (NASDAQ: MEDP) shares crashed 23% after its full-year results, despite revenues of US$2.5 billion matching predictions and profits exceeding expectations at US$15.28 per share. Analysts are now forecasting US$2.81 billion in revenue for 2026 with EPS of US$16.98, showing increased optimism for earnings, though they have cut the average price target by 10% to US$491. While revenue growth is expected to slow from historical rates, it is still projected to outpace the broader industry.
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts
Medpace (MEDP) provided its revenue growth outlook for 2026, projecting an increase of up to 12.8%. This forecast comes as the company anticipates a normalization of its backlog and shifts in metabolic trial engagement.
Krilogy Financial LLC Purchases New Holdings in Medpace Holdings, Inc. $MEDP
Krilogy Financial LLC acquired a new stake of 3,164 shares in Medpace Holdings, Inc. (NASDAQ:MEDP) during Q3, valued at approximately $1.63 million. Medpace exceeded Q4 earnings and revenue estimates and provided strong FY2026 EPS guidance, indicating continued growth despite significant insider selling and some analyst target trims that led to near-term selling pressure. The company's stock performance shows a 52-week range of $250.05 to $628.92, and analysts currently hold a "Hold" consensus rating with an average price target of $477.36.
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts
Medpace shared its 2026 financial outlook, projecting revenue growth of up to 12.8%. This forecast comes as the company anticipates a normalization of its backlog and adjustments in clinical trial focus, particularly concerning metabolic trials. Further details are expected to be discussed during their upcoming earnings call.
Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2025 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP) reported its Q4 and full-year 2025 earnings, with revenue reaching $708.5 million in Q4 (up 32% year-over-year) and $2.53 billion for the full year (up 20%). The company noted elevated backlog cancellations in Q4, resulting in a net book-to-bill ratio of 1.04, but expects continued growth and plans to increase hiring in 2026. Medpace also discussed changes in therapeutic mix, particularly the impact of metabolic trials on pass-through revenues, and addressed their cautious yet proactive approach to AI integration.
Madison Asset Management LLC Sells 4,419 Shares of Medpace Holdings, Inc. $MEDP
Madison Asset Management LLC reduced its stake in Medpace Holdings, Inc. by 1.5% in the third quarter, selling 4,419 shares and now holding 292,629 shares valued at $150.5 million. This aligns with significant insider selling from Medpace's CEO and VP, despite the company beating Q4 earnings and revenue estimates and raising its FY2026 guidance. The stock experienced a dip due to concerns about backlog normalization and timing shifts in metabolic trials, leading analysts to maintain a "Hold" rating with an average target price of $486.82.
Medpace Q4 Earnings Beat Overshadowed by Cancellation Spike
Medpace Holdings, Inc. reported strong Q4 2025 financial results, exceeding analyst estimates with significant revenue and GAAP net income growth. However, the positive earnings were tempered by an unexpected spike in project cancellations, particularly in the Metabolic therapeutic area, which led to a lower-than-anticipated net book-to-bill ratio. Management acknowledged the elevated cancellations but expressed hope they would not continue, with CEO August Troendle stating, "Only time will tell."
Leerink Partners lowers Medpace stock price target on elevated cancellations
Leerink Partners has reduced its price target for Medpace (NASDAQ:MEDP) to $485.00 from $575.00 due to unexpectedly high cancellation rates in the fourth quarter, particularly in cardiometabolic trials. Despite this, Medpace maintains strong financial health and recently reported impressive Q4 2025 results that surpassed analyst expectations in earnings and revenue. The lowered price target reflects increased uncertainty despite management's view that the business environment is unchanged.
U.S. Markets Ended Tuesday Mixed As Spotify Technology Led, Medpace Holdings Lagged
U.S. stock markets closed mixed on Tuesday, with some indexes showing slight gains and others experiencing declines. Spotify Technology was identified as a leading stock, while Medpace Holdings lagged behind. This broad performance indicates a varied day for the American markets.
Medpace Holdings Inc (NASDAQ:MEDP) Issues Inline Guidance
Medpace Holdings Inc (NASDAQ:MEDP) reported strong Q4 FY25 results, beating analyst expectations with increased net new business awards and significant revenue growth for the full year. Despite a slight dip in EBITDA margin, the company ended 2025 with substantial cash reserves and repurchase activity. Medpace's 2026 revenue outlook is largely in line with market predictions.
Earnings call transcript: Medpace Q4 2025 beats expectations, stock drops
Medpace Holdings Inc. (MEDP) reported strong Q4 2025 results, exceeding analyst expectations with an EPS of $4.67 and revenue of $708.5 million. Despite these positive figures, the stock dropped sharply by 13.92% in premarket trading due to investor concerns over elevated cancellation rates, particularly in the metabolic sector. The company projects 2026 revenue growth of 8.9% to 12.8% and is focusing on AI applications while managing operational risks.
Medpace Holdings, Inc. Q4 Income Advances, Beats Estimates
Medpace Holdings, Inc. (MEDP) reported a significant increase in its fourth-quarter profit, surpassing Street estimates. The company's earnings rose to $135.13 million, or $4.67 per share, compared to $117.02 million, or $3.67 per share, in the previous year, beating the analyst consensus of $4.23 per share. Revenue also saw a substantial increase of 32.0% to $708.45 million from $536.59 million year-over-year.
Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025
Medpace (NASDAQ:MEDP) reported strong Q4 CY2025 results, exceeding revenue and EPS estimates with a 32% year-on-year sales increase. The company also provided optimistic guidance for full-year 2026 revenue and EPS, surpassing analyst expectations. Despite a slight dip in operating margin, the company demonstrated solid long-term growth in both revenue and earnings per share, indicating healthy demand and effective cost management.
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. (Nasdaq: MEDP) announced strong financial results for the fourth quarter and full year ended December 31, 2025. The company reported a significant increase in revenue, net income, and EBITDA for both periods, driven by solid net new business awards and a healthy backlog. Medpace also provided optimistic financial guidance for 2026, projecting continued revenue growth and increased GAAP net income and EBITDA.
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
Medpace (MEDP) reported Q4 earnings of $4.67 per share, surpassing the Zacks Consensus Estimate of $4.18 and the previous year's $3.67. The company's revenues also exceeded expectations at $708.45 million, compared to an estimated $681.13 million. Despite these strong results, Medpace's shares have seen a 3.5% decline year-to-date, contrasting with the S&P 500's gain, and the stock currently holds a Zacks Rank #3 (Hold).
Earnings Flash (MEDP) Medpace Holdings, Inc. Reports Q4 Revenue $708.5M, vs. FactSet Est of $689.3M
Medpace Holdings, Inc. (MEDP) reported strong fourth-quarter revenue of $708.5 million, surpassing FactSet's estimate of $689.3 million. The company also announced its Q4 EPS at $4.67, exceeding the FactSet estimate of $4.19, and provided guidance for 2026 with expected EPS between $16.68 and $17.50 and revenue between $2.755 billion and $2.855 billion.
Medpace: Q4 Earnings Snapshot
Medpace Holdings Inc. (MEDP) reported strong fourth-quarter results, with net income of $135.1 million, or $4.67 per share, surpassing analyst estimates. The company also announced revenue of $708.5 million, exceeding Street forecasts. For the full year, Medpace anticipates earnings between $16.68 and $17.50 per share, with revenue ranging from $2.76 billion to $2.86 billion.
Medpace: Q4 Earnings Snapshot
Medpace Holdings Inc. (MEDP) reported strong fourth-quarter earnings, with net income of $135.1 million, or $4.67 per share, exceeding Wall Street estimates. The company also surpassed revenue expectations, posting $708.5 million for the quarter. For the full year, Medpace reported a profit of $451.1 million on revenue of $2.53 billion and provided an optimistic outlook for full-year 2026 earnings and revenue.
Medpace Set to Release Q4 Earnings on February 9th
Medpace (MEDP) is scheduled to release its Q4 earnings on February 9th, with analysts forecasting a 14.2% year-over-year EPS increase to $4.19 and revenue growth of 28.8% to $690.93 million. Historically, Medpace has frequently surpassed EPS and revenue estimates, though recent estimate revisions indicate a cautious market outlook. Wall Street analysts have an average 1-year price target of $569.17 for MEDP, with an overall "Hold" rating.
Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow
Medpace Holdings (MEDP) is set to announce its Q4 earnings on Monday afternoon. Analysts anticipate a 27.9% year-on-year revenue growth to $686.1 million and adjusted earnings of $4.23 per share. The company has a mixed record of beating revenue estimates, and the broader life sciences tools & services segment has seen underperformance recently.
Medpace (MEDP) Q4 2025 Earnings Preview: Revenue & Analyst Expectations - News and Statistics
Medpace Holdings (MEDP) is set to announce its Q4 2025 earnings, with analysts projecting a 27.9% year-on-year revenue growth to $686.1 million and adjusted earnings of $4.23 per share. Despite beating revenue expectations last quarter, the company has missed Wall Street's estimates four times in the past two years. The life sciences tools & services sector, including Medpace, has seen share price underperformance recently, with Medpace down 8.3% over the last month.
Rep. David Taylor Buys Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
Representative David Taylor (R-Ohio) recently purchased between $1,001 and $15,000 worth of Medpace Holdings (NASDAQ:MEDP) stock on January 29, 2026, as disclosed on February 2. This purchase was part of several trades made by Taylor on that day, including buying shares in other major companies and selling stakes in others. Despite Taylor's acquisition, Medpace currently holds a "Reduce" consensus rating from analysts with an average price target of $491.27, and company insiders have recently sold a significant number of shares.
Rep. David Taylor Sells Off Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)
Representative David Taylor (R-Ohio) recently sold between $1,001 and $15,000 of Medpace Holdings, Inc. (NASDAQ:MEDP) stock on January 16th, though he also made a purchase of the same stock on January 29th, alongside other tech and retail giants. Medpace analysts currently rate the stock a "Reduce" with an average price target of $491.27, despite some institutional investors increasing their positions. The company has a current market capitalization of $16.02 billion and a P/E ratio of 39.76.
Federated Hermes Inc. Cuts Stock Holdings in Medpace Holdings, Inc. $MEDP
Federated Hermes Inc. significantly reduced its stake in Medpace Holdings, Inc. by 62.4% in the third quarter, selling nearly 20,000 shares. This divestment comes amidst substantial insider selling, with company executives offloading over $205 million worth of shares in the last three months. Analysts, on average, rate Medpace as "Reduce" with a price target below its current trading price, despite institutional investors owning nearly 78% of the stock.
Mawer Investment Management Ltd. Sells 170,658 Shares of Medpace Holdings, Inc. $MEDP
Mawer Investment Management Ltd. reduced its stake in Medpace Holdings, Inc. by 20.9% in the third quarter, selling 170,658 shares and now owning 646,774 shares valued at $332.5 million. Concurrently, Medpace insiders, including President Jesse J. Geiger and VP Susan E. Burwig, have also sold significant amounts of company stock. Despite a "Reduce" consensus rating from analysts and an average target price of $491.27, some firms have increased their price targets for Medpace.
Medpace (MEDP) to Release Earnings on Monday
Medpace (NASDAQ:MEDP) is scheduled to release its Q4 2025 earnings after market close on Monday, February 9th, with analysts expecting $4.18 EPS and $689.53 million in revenue. The company's stock opened at $582.48, and insiders have recently sold a significant number of shares, though they still retain a substantial ownership stake. Institutional investors have also adjusted their holdings, and the consensus analyst rating for Medpace is "Reduce" with an average target price of $491.27.
Medpace Investors Await Key Financial Report
Medpace Holdings, Inc. will release its Q4 and full-year 2025 financial results on February 9, 2026, after market close, followed by a conference call on February 10, 2026, at 3:00 p.m. CET. This report is crucial as the clinical research organization navigates significant industry shifts, including the integration of AI, automation, and decentralized trial models. Investors will focus on the company's ability to adapt to these changes and its strategies for profitable growth.
Retirement Systems of Alabama Has $32.24 Million Stake in Medpace Holdings, Inc. $MEDP
Retirement Systems of Alabama decreased its stake in Medpace Holdings, Inc. by 3.1% in Q3 2025, now holding 62,695 shares valued at $32.24 million. Despite significant institutional ownership (77.98%) and some buys from major firms, there has been substantial insider selling totaling $211.28 million in the last 90 days. Analysts currently have a "Reduce" consensus rating for Medpace, with a target price of $491.27.
Teacher Retirement System of Texas Sells 5,245 Shares of Medpace Holdings, Inc. $MEDP
The Teacher Retirement System of Texas recently reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.4%, selling 5,245 shares and retaining 16,263 shares valued at approximately $8.36 million. This move comes as Medpace stock has seen significant institutional and insider trading activity, with insiders recently being net sellers. Despite a "Reduce" consensus rating and a target price below its current trading value, several analysts have adjusted their price objectives, reflecting varied outlooks on the company.
Wealth Enhancement Advisory Services LLC Acquires 9,117 Shares of Medpace Holdings, Inc. $MEDP
Wealth Enhancement Advisory Services LLC significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, purchasing 9,117 additional shares and bringing its total holdings to 15,193 shares valued at approximately $8.08 million. This move is part of broader institutional interest in Medpace, though insider selling has also been noted. The article also provides an overview of analyst ratings, Medpace's financial performance, and company profile.
4,962 Shares in Medpace Holdings, Inc. $MEDP Acquired by Trek Financial LLC
Trek Financial LLC has acquired 4,962 shares of Medpace Holdings, Inc. (NASDAQ:MEDP), valued at approximately $2.55 million in the third quarter. Despite significant insider selling totaling over $233 million, institutional ownership remains high at nearly 78%, though analysts have a "Reduce" consensus rating with a target price below the current market value. Medpace recently reported strong Q3 earnings, beating estimates and showing substantial year-over-year revenue growth.
Medpace Holdings, Inc. $MEDP Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.2% in the 3rd quarter, selling 3,271 shares and retaining 21,416 shares valued at $11 million. This comes amidst significant insider selling from Medpace executives and a "Reduce" consensus rating from analysts, despite the company beating Q3 earnings and revenue estimates. Other large institutional investors, however, increased their positions in the company.
Baillie Gifford & Co. Purchases 62,503 Shares of Medpace Holdings, Inc. $MEDP
Baillie Gifford & Co. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.0%, acquiring 62,503 additional shares, bringing their total ownership to 584,796 shares valued at $300.7 million. This increase in institutional ownership contrasts with significant insider selling from Medpace's VP and CEO, who sold shares totaling over $47 million. Despite Medpace beating Q3 earnings expectations, the stock trades at a premium with a "Reduce" consensus rating and a target price of $491.27 from analysts.
Medpace (MEDP) Stock Drops Despite Market Gains: Important Facts to Note
Medpace (MEDP) stock fell 3.01% to $588.05 in its latest session, underperforming the S&P 500, despite a 6.02% climb over the past month. Investors are anticipating the company's Q4 2025 earnings report on February 9, 2026, with an expected EPS growth of 13.9% and revenue increase of 26.94%. The stock currently holds a Zacks Rank of #4 (Sell) and trades at a premium valuation compared to its industry.
NorthCrest Asset Manangement LLC Makes New $1.06 Million Investment in Medpace Holdings, Inc. $MEDP
NorthCrest Asset Management LLC has acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP), purchasing 1,996 shares valued at approximately $1.06 million during the third quarter. This investment comes amidst significant insider selling, with the company's President and CEO selling large blocks of shares, and a mixed analyst sentiment, as the stock holds an average "Reduce" rating despite beating Q3 earnings and revenue estimates. Other institutional investors have also adjusted their positions in Medpace, with overall institutional ownership at 77.98%.
QRG Capital Management Inc. Sells 10,489 Shares of Medpace Holdings, Inc. $MEDP
QRG Capital Management Inc. has significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by selling 10,489 shares, leaving them with 2,886 shares valued at approximately $1.484 million. This move comes amidst active selling by company insiders, including the CFO and CEO, who have disposed of over 387,000 shares worth $233.4 million in the last three months. Despite Medpace beating quarterly earnings estimates, Wall Street analysts maintain a "Reduce" average rating with a consensus price target below the stock's recent trading level.
Berkeley Inc Decreases Stake in Medpace Holdings, Inc. $MEDP
Berkeley Inc. significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 44.9% in the third quarter, selling 2,172 shares. Despite Medpace's strong quarterly earnings, outperforming analyst expectations, the stock receives a consensus "Reduce" rating with an average target price below its current trading level. Institutional investors collectively own a substantial portion of the company, and there has been notable insider selling activity recently.
